Worsening of clinical status · individuals with moderate to severe disease
Summary of Findings Table ‐ Vitamin D showed no clear difference in worsening of clinical status compared with placebo or standard care alone (low certainty).
1 finding from 1 review
Quality of life, including fatigue and neurological functioning; · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: all grades · individuals with moderate to severe disease
It is very uncertain whether summary of Findings Table ‐ Vitamin D changes adverse events (any grade) compared with placebo or standard care alone (very low certainty).
1 finding from 1 review
Serious adverse events · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality assessed up to day 28 · individuals with moderate or severe COVID‐19
1 finding from 1 review
Time to resolution · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Serious adverse events within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · individuals with moderate or severe COVID‐19
1 finding from 1 review
Improvement of clinical status: participants discharged alive up to day 28 without clinical deterioration or death · individuals with moderate or severe COVID‐19
1 finding from 1 review
Quality of life, including fatigue and neurological functioning; · individuals with moderate or severe COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ( · individuals with moderate or severe COVID‐19
1 finding from 1 review
Serious adverse events ( · individuals with moderate or severe COVID‐19
1 finding from 1 review
All‐cause mortality up to day 28 · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Admission to hospital or death within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Resolution of symptoms · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival · Individuals with Hodgkin lymphoma
The intervention probably leads to higher overall survival (moderate certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival · Individuals with Hodgkin lymphoma
It is very uncertain whether the intervention changes progression‐free survival (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events associated with PET ‐ not reported · Individuals with Hodgkin lymphoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found